CannPal Successfully Imports Cannabis Oils for Clinical Trial of Lead Drug Candidate
- CannPal has been granted export permits by Health Canada for its medical cannabis oil formulations
- Oils have now arrived in Sydney, Australia and are in transit to a purpose-built research facility for the clinical phase of the Company’s research
- cGMP accredited licensed producer Aphria Inc (TSE:APH), has provided the clinical trial material for the studies
- CannPal has completed the dog selection process and is in the last stage of preparation for the live phase of its research
- CannPal is assessing the pharmacokinetic and safety profile of its proprietary cannabinoid formulations
- The live phase of the research is set to commence on the week starting April 2nd
27th March 2018: Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce that it has imported its first medical cannabis oil formulations, having recently received export permits from Health Canada. The oils will be used in the clinical phase of research for the Company’s lead drug candidate,CPAT-01.
Aphria Inc. (TSE:APH) (“Aphria”) is providing the clinical trial material for the Company’s studies. Aphria recently became the first Canadian licensed producer to receive current Good Manufacturing Practice (cGMP) accreditation from internationally renowned firm SGS. The certification is to United States Food and Drug Administration (USFDA) cGMP standards,
which are internationally-recognised for the safe and consistent production of pharmaceutical grade medicines.
CannPal has completed the dog selection process for the live phase of the research and is in the last stage of preparation for the study, which is being carried out in a purpose-built research facility in NSW. CannPal has entered into service agreements with a number of specialised pharmaceutical analytical companies to complete various bioanalytical services for the study.
The study will be carried out in 2 phases, with 11 dogs enrolled for phase 1 and 48 dogs enrolled for phase 2. Researchers will be assessing the pharmacokinetic and safety profiles for the Company’s proprietary cannabinoid formulations, with blood sample analysis expected to be completed by May 2018.
Dosing of the dogs is expected to commence on the week starting April 2nd.